KHN Morning Briefing

Summaries of health policy coverage from major news organizations.

Amgen Drug Gets Boost In Fiscal Cliff Legislation

The New York Times: Medicare Pricing Delay Is Political Win For Drug Maker
Just two weeks after pleading guilty in a major federal fraud case, Amgen, the world's largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the "fiscal cliff" bill that did not mention the company by name but strongly favored one of its drugs. The language buried in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, a lucrative Amgen pill used by kidney dialysis patients (Lipton and Sack, 1/19).

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.